
Neogen (NEOG) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: May 2025Income Metrics
Revenue
225.5M
Gross Profit
92.9M
41.18%
Operating Income
-13.3M
-5.88%
Net Income
-612.2M
-271.53%
Balance Sheet Metrics
Total Assets
3.4B
Total Liabilities
1.4B
Shareholders Equity
2.1B
Debt to Equity
0.66
Cash Flow Metrics
Operating Cash Flow
-595.7M
Free Cash Flow
406.0K
Revenue & Profitability Trend
Neogen Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 894.7M | 924.2M | 822.4M | 527.2M | 468.5M |
Cost of Goods Sold | 473.3M | 460.3M | 416.5M | 284.1M | 253.4M |
Gross Profit | 421.4M | 463.9M | 406.0M | 243.0M | 215.1M |
Gross Margin % | 47.1% | 50.2% | 49.4% | 46.1% | 45.9% |
Operating Expenses | |||||
Research & Development | 21.1M | 22.5M | 26.0M | 17.0M | 16.2M |
Selling, General & Administrative | 402.0M | 382.8M | 342.4M | 167.3M | 124.6M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 423.1M | 405.2M | 368.4M | 184.4M | 140.9M |
Operating Income | -1.7M | 58.7M | 37.5M | 58.6M | 74.2M |
Operating Margin % | -0.2% | 6.3% | 4.6% | 11.1% | 15.8% |
Non-Operating Items | |||||
Interest Income | 3.1M | 6.4M | 3.2M | 1.3M | 1.7M |
Interest Expense | 71.6M | 73.4M | 56.0M | 72.0K | 78.0K |
Other Non-Operating Income | -3.6M | -5.9M | -6.8M | 322.0K | -515.0K |
Pre-tax Income | -1.1B | -14.3M | -22.0M | 60.2M | 75.3M |
Income Tax | -41.1M | -4.9M | 828.0K | 11.9M | 14.4M |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 19.8% | 19.1% |
Net Income | -1.1B | -9.4M | -22.9M | 48.3M | 60.9M |
Net Margin % | -122.1% | -1.0% | -2.8% | 9.2% | 13.0% |
Key Metrics | |||||
EBITDA | 123.5M | 180.3M | 124.4M | 84.4M | 96.4M |
EPS (Basic) | $-5.03 | $-0.04 | $-0.12 | $0.45 | $0.57 |
EPS (Diluted) | $-5.03 | $-0.04 | $-0.12 | $0.45 | $0.57 |
Basic Shares Outstanding | 216894861 | 216481878 | 188880836 | 107801094 | 107468304 |
Diluted Shares Outstanding | 216894861 | 216481878 | 188880836 | 107801094 | 107468304 |
Income Statement Trend
Neogen Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 129.0M | 170.6M | 163.2M | 44.5M | 75.6M |
Short-term Investments | 0 | 325.0K | 82.3M | 336.6M | 305.5M |
Accounts Receivable | 153.4M | 173.0M | 153.3M | 99.7M | 91.8M |
Inventory | 190.9M | 189.3M | 133.8M | 122.3M | 100.7M |
Other Current Assets | 53.3M | 56.0M | 53.3M | 23.8M | 17.8M |
Total Current Assets | 576.9M | 589.2M | 585.9M | 626.8M | 591.5M |
Non-Current Assets | |||||
Property, Plant & Equipment | 17.2M | 14.8M | 11.9M | 3.2M | 2.5M |
Goodwill | 3.5B | 5.8B | 5.9B | 392.9M | 355.3M |
Intangible Assets | 1.4B | 1.5B | 1.6B | 107.5M | 92.3M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 35.2M | 20.4M | 15.2M | 2.2M | 2.0M |
Total Non-Current Assets | 2.9B | 4.0B | 4.0B | 366.1M | 328.7M |
Total Assets | 3.4B | 4.5B | 4.6B | 992.9M | 920.2M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 79.6M | 83.1M | 76.7M | 34.6M | 23.9M |
Short-term Debt | 19.3M | 2.4M | - | - | - |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 38.7M | 22.8M | 20.9M | - | - |
Total Current Liabilities | 174.0M | 154.3M | 145.5M | 77.8M | 53.6M |
Non-Current Liabilities | |||||
Long-term Debt | 874.8M | 888.4M | 885.4M | - | - |
Deferred Tax Liabilities | 280.9M | 326.7M | 353.4M | 17.0M | 21.9M |
Other Non-Current Liabilities | 42.9M | 35.3M | 35.9M | 10.7M | 4.3M |
Total Non-Current Liabilities | 1.2B | 1.3B | 1.3B | 27.7M | 26.2M |
Total Liabilities | 1.4B | 1.4B | 1.4B | 105.6M | 79.8M |
Equity | |||||
Common Stock | 34.7M | 34.7M | 34.6M | 17.2M | 17.2M |
Retained Earnings | -536.4M | 555.6M | 565.0M | 587.9M | 539.6M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 2.1B | 3.1B | 3.1B | 887.4M | 840.4M |
Key Metrics | |||||
Total Debt | 894.1M | 890.8M | 885.4M | 0 | 0 |
Working Capital | 402.9M | 434.9M | 440.5M | 549.0M | 537.9M |
Balance Sheet Composition
Neogen Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -1.1B | -9.4M | -22.9M | 48.3M | 60.9M |
Depreciation & Amortization | 125.7M | 121.2M | 90.5M | 24.1M | 21.0M |
Stock-Based Compensation | 17.3M | 13.8M | 10.2M | 7.2M | 6.4M |
Working Capital Changes | -4.5M | -83.6M | -25.1M | -367.0K | -3.2M |
Operating Cash Flow | -1.0B | 23.2M | 40.6M | 72.1M | 84.5M |
Investing Activities | |||||
Capital Expenditures | -99.5M | -111.3M | -64.9M | -24.4M | -26.7M |
Acquisitions | 0 | 0 | 11.7M | -38.7M | -50.8M |
Investment Purchases | 0 | 0 | -12.5M | -415.9M | -792.7M |
Investment Sales | 325.0K | 82.0M | 266.8M | 381.8M | 764.6M |
Investing Cash Flow | -99.2M | -29.3M | 201.0M | -97.2M | -105.6M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | 0 |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 550.0M | - | - | - | - |
Debt Repayment | -550.3M | 0 | -100.0M | 0 | 0 |
Financing Cash Flow | -3.8M | -538.0K | -119.3M | -1.1M | -1.1M |
Free Cash Flow | -46.4M | -76.2M | -24.7M | 43.6M | 54.4M |
Net Change in Cash | -1.1B | -6.6M | 122.3M | -26.3M | -22.2M |
Cash Flow Trend
Neogen Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
865.00
Forward P/E
9.51
Price to Book
0.59
Price to Sales
1.36
PEG Ratio
9.51
Profitability Ratios
Profit Margin
-122.06%
Operating Margin
-4.97%
Return on Equity
-41.88%
Return on Assets
0.01%
Financial Health
Current Ratio
3.32
Debt to Equity
44.14
Beta
1.79
Per Share Data
EPS (TTM)
$-5.03
Book Value per Share
$9.54
Revenue per Share
$4.13
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
neog | 1.2B | 865.00 | 0.59 | -41.88% | -122.06% | 44.14 |
Thermo Fisher | 184.1B | 28.17 | 3.64 | 13.42% | 15.24% | 69.62 |
Danaher | 151.0B | 44.88 | 2.89 | 6.68% | 14.21% | 35.45 |
Twist Bioscience | 1.7B | -7.35 | 3.53 | -17.58% | -23.52% | 19.48 |
Grail | 1.1B | -0.49 | 0.49 | -17.68% | -62.12% | 2.69 |
Opko Health | 1.1B | -17.13 | 0.82 | -13.16% | -26.68% | 30.51 |
Financial data is updated regularly. All figures are in the company's reporting currency.